Patents by Inventor Virender Kumar Sarin

Virender Kumar Sarin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rapid-acting insulin compositions
    Patent number: 11872266
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: January 16, 2024
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20220072105
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schutte, Ranajoy Majumdar
  • Rapid-acting insulin compositions
    Patent number: 11123406
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20210169988
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • Rapid-acting insulin compositions
    Patent number: 10925931
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20190231851
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Application
    Filed: May 14, 2018
    Publication date: August 1, 2019
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • Rapid-acting insulin compositions
    Patent number: 9993555
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: June 12, 2018
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20180140676
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 24, 2018
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • Rapid-acting insulin compositions
    Patent number: 9901623
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 27, 2018
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20170056478
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Application
    Filed: August 19, 2016
    Publication date: March 2, 2017
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • RAPID-ACTING INSULIN COMPOSITIONS
    Publication number: 20160166695
    Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 16, 2016
    Inventors: MICHAEL PATRICK AKERS, CHI A. NGUYEN, CHAD D. PAAVOLA, VIRENDER KUMAR SARIN, NANETTE ELIZABETH SCHULTE, RANAJOY MAJUMDAR
  • GLP-1 formulations with protracted time action
    Patent number: 7144863
    Abstract: The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: December 5, 2006
    Assignee: Eli Lilly and Company
    Inventors: Michael Rosario DeFelippis, Henry Acken Havel, Kenneth F. Mace, Kingman Ng, Virender Kumar Sarin
  • Fatty acid -- pulmonary surfactant conjugates
    Patent number: 6022955
    Abstract: This invention discloses a method for chemically modifying a pulmonary surfactant protein or polypeptides with various fatty acids. These conjugates are useful in preparing formulations for the treatment of respiratory disease.
    Type: Grant
    Filed: December 10, 1991
    Date of Patent: February 8, 2000
    Assignee: Abbott Laboratories
    Inventors: Virender Kumar Sarin, Darryl Robin Absolom, Shanker Lal Gupta
  • Pulmonary surfactant protein fragments
    Patent number: 5753621
    Abstract: This invention discloses that certain fragments of a pulmonary surfactant protein exhibit unexpected surface activity. These protein fragments are useful in preparing formulations for the treatment of respiratory distress syndrome.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: May 19, 1998
    Assignee: Abbott Laboratories
    Inventors: Madhup Krishna Dhaon, Edwin Orville Lundell, Virender Kumar Sarin, Constance Hope Baxter, Darryl Robin Absolom
  • Fatty acid - pulmonary surfactant conjugates
    Patent number: 5700777
    Abstract: This invention discloses a method for chemically modifying a pulmonary surfactant protein or polypeptides with various fatty acids. These conjugates are useful in preparing formulations for the treatment of respiratory disease.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: December 23, 1997
    Assignee: Abbott Laboratories
    Inventors: Virender Kumar Sarin, Darryl Robin Absolom, Shanker Lal Gupta